MA-PERKINELMER
9.3.2021 14:02:14 CET | Business Wire | Press release
PerkinElmer, Inc. (NYSE:PKI) today announced the launch of two Research Use Only (RUO) solutions, PKamp™ VariantDetect™ SARS-CoV-2 RT-PCR Assay and Next Generation Sequencing-based NEXTFLEX® Variant-Seq™ SARS-CoV-2 Kit . Using nucleic acid extracted from samples that previously tested positive, laboratories can use these assays to identify genomic mutations reported in relation to SARS-CoV-2 variants.
Public health agencies such as the U.S. Food and Drug Administration (FDA) have alerted clinical laboratories and the healthcare community about SARS-CoV-2 viral mutations. Upon detecting a positive case using a first-tier diagnostic assay, second-tier assays such as the PerkinElmer PKamp VariantDetect and NEXTFLEX Variant-Seq kits provide further information about mutations in the sample. The PKamp VariantDetect SARS-CoV-2 RT-PCR assay can detect mutations associated with B.1.1.7, B.1.351 and P.1 variants, which are the predominant variant strains known today. The NEXTFLEX Variant-Seq SARS-CoV-2 WGS workflow can detect all SARS-CoV-2 genetic changes relative to the strain originally identified in Wuhan, China.
“While continuing to rely on gold-standard RT-PCR tests for COVID-19 diagnosis, we must understand emerging variants to effectively limit the spread of the virus,” said Masoud Toloue, Ph.D., senior vice president, diagnostics, PerkinElmer. “The second-tier assays made available today are the outcome of a product development engine primed to continue producing assays that will help labs outpace the virus.”
PerkinElmer continues to work on the frontlines of improving COVID-19 testing. The PerkinElmer® New Coronavirus Nucleic Acid Detection Kit is the most sensitive molecular test for COVID-19 on the market, according to comparative data released by a FDA Reference Panel , and can be used to test symptomatic or asymptomatic individuals, individually or in pools of up to five samples. The Company’s comprehensive SARS-CoV-2 offerings also include high throughput RNA extraction , RT-PCR , antigen testing , workflow automation , ELISA , chemiluminescence , time-resolved fluorescence and lateral flow based serology testing .
About PerkinElmer
PerkinElmer enables scientists, researchers, and clinicians to address their most critical challenges across science and healthcare. With a mission focused on innovating for a healthier world, we deliver unique solutions to serve the diagnostics, life sciences, food, and applied markets. We strategically partner with customers to enable earlier and more accurate insights supported by deep market knowledge and technical expertise. Our dedicated team of about 14,000 employees worldwide is passionate about helping customers work to create healthier families, improve the quality of life, and sustain the wellbeing and longevity of people globally. The Company reported revenue of approximately $3.8 billion in 2020, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available through 1-877-PKI-NYSE, or at www.perkinelmer.com
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210309005334/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA25.8.2026 16:40:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 statusRegimen poised to become standard of care in this difficult-to-treat disease. BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The approval is supported by results from the Phase 3 HERIZON-GEA-01 trial, which were published in The New England Journal of Medicine earlier this year. GEA, which includes adenocarcinomas of the stomach, gastroesophageal junction and e
Gatik Raises $200 Million; Series D Led by QIA and KDT as Demand for Driverless Commercial Freight Accelerates25.8.2026 15:00:00 CEST | Press release
Gatik, the leader in autonomous trucking, today announced $200 million in financing as demand accelerates for driverless commercial freight across Fortune 50 retail, grocery and CPG supply chains. The Series D round was led by Qatar Investment Authority (QIA) and Koch Disruptive Technologies (KDT), with participation from Millennium Management, ARK Invest, Intact Private Capital and others. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260825490075/en/ Gatik Announces Series D round Gatik has built one of the most commercially advanced businesses in autonomous freight, with more than $600 million in contracted revenue, 85,000 fully driverless orders completed, and 99% on-time delivery across its operations. Its trucks move goods across high-frequency regional networks between distribution centers and stores, giving customers a reliable way to add capacity, improve service levels and keep products moving. “This round, led by
Safe Software Opens Registration for the Peak of Data and AI 2027 With More Accessible Access Packages25.8.2026 15:00:00 CEST | Press release
Free passes for public sector professionals, new one-day options, and lower pricing across every pass type open the London conference up to a wider audience. Safe Software (Safe), creator of FME, the only All-Data, Any-AI enterprise integration platform, has announced that registration is open for the Peak of Data and AI 2027, its global conference for data and AI professionals, taking place March 9 to 11, 2027 at the QEII Centre in London, UK. The news builds on Safe's announcement in March 2026 that London would host the biennial conference, which has previously been held in Vancouver, Canada, Bonn, Germany and Seattle, Washington, and draws attendees from North America, Europe, Asia-Pacific, and beyond. Alongside opening registration, Safe has introduced a revised set of access packages designed to bring a broader range of professionals to the event: Free passes for public sector and government professionals, from any country One-day passes, for attendees who are unable to join for
SLB Selected as Strategic Reservoir Partner for the Havstjerne Carbon Storage Project25.8.2026 14:46:00 CEST | Press release
Integrated engineering work will support development of the large-scale carbon storage project ahead of a final investment decision Global energy technology company SLB (NYSE: SLB) today announced it has been selected as strategic reservoir partner for the Havstjerne carbon storage project in the Norwegian North Sea, providing technology and engineering services for the concept and front-end engineering and design (FEED) phases. The Havstjerne project is a large-scale offshore carbon storage development in Norway intended to serve industrial emitters across Europe, operated by Harbour Energy (LSE: HBR) in consortium with Stella Maris CCS, a Yinson Production company. SLB will coordinate an integrated project scope that connects analysis of the underground storage reservoir with injection well design, subsea infrastructure and plans for monitoring stored CO2 as the Havstjerne partnership develops the project’s technical, cost and schedule basis ahead of a final investment decision. The
Moody’s Brings Its Decision-Grade Intelligence to Gemini Enterprise for Financial Services25.8.2026 14:05:00 CEST | Press release
Integration through Moody’s Credit MCP server brings trusted credit ratings, research, and entity intelligence into Google Cloud’s new industry-specific AI solution for financial services Moody’s Corporation (NYSE: MCO) today announced that its connected intelligence is now available in Google Cloud’s Gemini Enterprise for Financial Services through the Moody’s Credit Model Context Protocol (MCP) server. As a launch partner for Google Cloud’s Gemini Enterprise for Financial Services, Moody’s gives financial professionals working in the platform direct access to credit ratings and research from Moody’s Ratings, along with Moody’s curated intelligence on companies, entities, and risk. “Delivering decision-grade intelligence wherever financial professionals work is how we help our customers stay ahead as agentic AI reshapes financial workflows,” said Ana Meauta, Managing Director, Channel Sales Partnerships at Moody’s. “With Gemini Enterprise for Financial Services, our customers can acce
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom